News: CUV UPDATE 1-U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment, page-104

Any risk/benefit analysis seems to indicate short sellers have got it wrong here IMO and your $50 fair value is not too far away.

Some notes on Clinuvel:
*Profitable and holding about $60 million cash (this would be a major reason for shorting a company if these factors were absent)
*Sales into worlds biggest EPP market imminent - perhaps next week.
*Plenty of EU growth to come including France, perhaps UK
*TGA application in progress for future Australian sales
*Upcoming FDA meeting for Vitiligo (massive future growth here)
*DNA repair seems like massive future potential
*VP plus another indication soon hopefully (more growth)
*Broker sphene has them valued over $50, Moelis over $30 and even morningstar quant has them over $30
*Current share price seems attractive IMO, not paying a premium price by any means and compares well to other biotechs
*Overall massive growth ahead and EPS growth ahead of what is already a profitable outfit
*About 4.7 million shares must be bought back by shortsellers who would seem to have an average sell price of circa $25

Some notes on the short sellers:
*They have already sold about 9.5% of fake shares into the market of CUV and depressed its price
*Price drop in large part due to shorts - no directors, large holders declaring any sales
*Possibly not too many fake borrowed shares left to short
*They have a pretty low sale price of not much more than $25 so they continue to short to keep price in check
*They have picked a tight register who seems to hold onto their shares and they can't close short positions without losing
*They have picked a profitable, cashed up outfit with massive GROWTH to come - totally wrong choice of stock to short
*Shorts have been stubborn but EPS growth over coming years will force them to buyback the fake shares
*Could have shorted 80% or more other companies and closed position and made money by now but look like losing here with CUV
*Seems that most of selling volume on a daily basis is from shorts
*Why were they shorting from 9/3 to 13/3 - took price from $15.82 to $14.81 but it required 0.72% of fake/borrowed shares to do this - that is some 350000 shares sold into a lightly traded stock! Missed opportunity to buyback there and how will they make money on those sales.

All IMO and DYOR. Obviously COVID 19 adds a huge uncertainty to everything, but healthcare is probably the best segment to be invested in right now as it has been for the last decade or more. Possible large short/ bot attack today and tomorrow leading into Easter break as this seems to be a favoured tactic of creating fear over a long weekend and hoping for some real sellers when trading resumes on Tuesday.